American multinational pharmaceutical corporation
POPULARITY
Categories
Valentine’s Day represents a perfect opportunity to highlight news and updates from across biopharma that have hearts all aflutter. In this week’s episode of “The Top Line,” we do just that, fueled by heart puns and holiday candy. Fierce’s Gabrielle Masson and Andrea Park discuss a new heart-focused biotech that recently emerged with $300 million and a cardiovascular drug that’s been named one of the most anticipated launches of 2025, as well as several other stories they’ve loved covering this year. To learn more about the topics in this episode: Kardigan launches with cozy $300M series A and collection of late-stage cardio assets Top 10 most anticipated drug launches of 2025 Cumberland's Duchenne drug improves blood flow from heart in phase 2 trial Novartis' first Super Bowl ad aims to 'create a movement' with breast cancer awareness blitz Don't call it a comeback: Pfizer returns to Super Bowl with ad pledging to 'knock out' cancer Takeda tightens reins on early-stage investments, looks to expand option deals: R&D head See omnystudio.com/listener for privacy information.
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novo's semaglutide shows promise in curbing alcohol use disorder, according to data published in JAMA Psychiatry. This supports the use of GLP-1 receptor agonists for addictive disorders. Meanwhile, the Trump administration is considering job cuts at the FDA. This could potentially lead to uncertainty and delays in regulatory reviews.In other news, Sanofi is facing a $250 million impairment after scrapping a J&J-partnered E. coli vaccine. Roche's Evrysdi has become the first pill cleared for spinal muscular atrophy. Pfizer has expanded the label for Adcetris to include non-Hodgkin lymphomas.Additionally, Newleos Therapeutics has raised $93.5 million to advance neuropsychiatric drugs from Roche's pipeline. All this information was shared by BioSpace, a platform that provides updates on the biotech and pharmaceutical industry.
Die Marketing- und Markennews der KW 7 mit folgenden Themen: Themen der Woche: - Ist Playmobil zurück? Im Rahmen der Spielwarenmesse gab es auch News rund um Playmobil: Neues Produktsystem Sky Trails, Anpassungen in Kommunikation & Medienmix, Festhalten an Produktlizenzen. Colin bleibt trotzdem skeptisch - aus Markenperspektive. Ein Grund: Die Antwort auf die Frage, was Playmobil eigentlich ist, bleibt offen. - Super Bowl: Viele Marken nutzen den Super Bowl als Bühne. Welche machen das gut? Welche weniger? Unicepta analysierte fast 7 Millionen Artikel und Posts. Ein Gewinner ist wohl Tubi, Verlierer ist Pfizer. Learning: Finden Sie die richtige Tonalität für den Super Bowl und achten Sie auf Glaubwürdigkeit und Passung. Gewinner der Woche: - Nike Fundstücke der Woche: - IKEA - Cadbury
Dr. David Speicher is a Canadian virologist with 20 years of experience in infectious disease diagnostics and molecular epidemiology. He currently serves as a senior research associate at the University of Guelph.During the COVID-19 pandemic, Dr. Speicher served as laboratory and R&D director of Multiplex Genomics, a COVID-19 PCR testing facility, while also teaching as a Sessional Assistant Professor at Redeemer University. In 2023, his research on Pfizer and Moderna COVID-19 modRNA vaccines gained international attention, including discussions in the U.S. Senate and European Parliament, contributing to policy discussions about vaccine safety.As a PPC candidate, Dr. Speicher advocates for evidence-based medical science, transparency in public health directives, and support for vaccine-injured Canadians through a comprehensive public inquiry into pandemic management.February 12, 2025
https://www.fda.gov/media/150386/downloadFollow me for more content on these platforms!Twitter- https://twitter.com/Insideforwalls
The Role of Clinicians in Addressing Climate Change: Dr. Catharina Giudice, Climate and Human Health Fellow, Harvard T.H. Chan School of Public Health “The healthcare system is in this interesting intersection when it comes to its roles and responsibilities as it pertains to climate change,” says our Raise the Line guest Dr. Catharina Giudice, a research fellow in climate and human health at Harvard University. As she explains to host Hillary Acer, the medical industry is a major producer of the greenhouse gasses that are contributing to serious health impacts on patients, especially those who are already vulnerable due to pre-existing conditions and economic struggles. Giudice, whose academic work focuses on healthcare sector climate preparedness, believes this paradox requires a response from clinicians. “There's so many small things that you can do as an individual clinician to make a difference in the climate change intersection.” Options include working to change hospital practices, educating peers and patients on the health impacts of climate change, and advocacy in the public policy arena. In this thought-provoking installment in our NextGen Journeys series, you'll also learn how the healthcare delivery system is being affected by climate change, and about a new concentration in climate change and planetary health at the Harvard T.H. Chan School of Public Health.Mentioned in this episode:Harvard T.H. Chan School of Public HealthHarvard University Center for the EnvironmentPractice Greenhealth If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast
Buckle up—this episode is coming in hot! As Pfizer continues its slow release of Covid-19 mRNA vaccine study data, we dig into what's been uncovered so far.Today's guest, Sasha Latypova, a former pharmaceutical industry executive with over 20 years in clinical research and regulatory affairs, shares her findings from the first 400 pages released through a FOIA request. Her analysis raises serious concerns, including whether Pfizer ever conducted proper safety testing and the CDC/FDA's claims that the vaccine “stays in the injection site.” Spoiler: The data suggests otherwise. We're linking the full Pfizer documents on our website so you can see the data for yourself!
This episode covers: Cardiology This Week: A concise summary of recent studies Atrial fibrillation in athletes 'Work and life' of a medical journalist Mythbusters: Female doctors with better outcomes Host: Perry Elliott Guests: Carlos Aguiar, Isabelle van Gelder, Shelley Wood Want to watch that episode? Go to: https://esc365.escardio.org/event/1799 Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel, Isabelle van Gelder and Shelley Wood have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Host: Perry Elliott Guest: Isabelle van Gelder Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1799?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Isabelle van Gelder have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Check out our new podcast ‘Ripples' on Microcultures from the links
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Novartis has paid $925 million upfront to acquire Anthos Therapeutics, a company it previously backed in February 2019. This acquisition is part of Novartis' strategy to buy back its drug, a blood thinner, and the entire company. In other news, Merck KGaA is in talks with SpringWorks for a potential acquisition, Lilly has signed deals with Olix Pharmaceuticals and Advancell, and there is a thriving shadow market of GLP-1s for weight loss causing regulatory concerns. Additionally, Vertex is expanding access for JourNavX, Pfizer has positive phase I data for a prostate cancer drug, and Inventiva is halving its workforce to focus on a specific candidate. Boehringer Ingelheim's lung fibrosis drug has scored a second late-stage win, Bain is investing in the Japanese market with a $3.3 billion Tanabe buy, and there is a decline in women leaders in biotech.
Comment les rhumatologues peuvent-ils gérer la prescription d'un vaccin en tenant compte des traitements immunosuppresseurs ? Quel est le délai recommandé pour vacciner un patient ayant récemment contracté une infection, et pourquoi ? Quels sont les conseils pour motiver les patients qui hésitent ou ont des inquiétudes face aux vaccins ? Comment adapter les recommandations vaccinales en fonction des spécificités des patients en rhumatologie ? Le Professeur Jacques Morel, rhumatologue au CHU de Montpellier et responsable du centre de référence des maladies auto-immunes, nous éclaire à ce sujet. Notre invité déclare avoir des liens d'intérêt avec : Bristol Myers Squibb, Celltrion, Lilly, Novartis, Pfizer, Sanofi, Merck Sharp and Dohme, Abbvie, Fresenius Kabi, Mylan, Boehringer Ingelheim, Galapagos, Glaxo Smith Kline, Roche, Union Chimique Belge, Janssen, Medac, Sandoz, Nordic Pharma. L'équipe : Comité scientifique : Pr Jérémie Sellam, Pr Thao Pham, Dr Catherine Beauvais, Dr Véronique Gaud Listrat, Dr Nicolas Poursac, Dr Céline Vidal, Dr Margaux Moret. Animation : Marguerite de Rodellec Production : MedShake Studio Soutien institutionnel : Pfizer
Megyn Kelly is joined by the hosts of The Daily Wire's "Crain & Company" to discuss Taylor Swift getting booed at the Super Bowl, her political turn failing and bringing many Americans out against her, the massive positive reaction President Trump got at the Super Bowl, the unsuccessful halftime performance of Kendrick Lamar, the media trying to make criticism of the performance racial, Pfizer and Bud Light trying to counter past bad press with new Super Bowl ads, great ads from Jeep and Uber Eats, and more. Then Megyn Kelly takes viewers and listeners behind the scenes to discuss her experience at the Super Bowl, her near run-in with Taylor Swift outside the bathroom, her impromptu meeting with President Trump, and her positive interactions with Karoline Leavitt and Donald Trump Jr., then addresses the ridiculous attacks on Trump and Elon Musk over the DOGE cuts.Crain & Company- https://www.dailywire.com/show/crain-and-companyFirecracker Farm: Get 10% off with code MK at https://Firecracker.Farm/Byrna: Get 10% Off at https://Byrna.com/MegynWe Heart Nutrition: Use code MEGYN for 20% off your first order at https://WeHeartNutrition.comFollow The Megyn Kelly Show on all social platforms:YouTube: https://www.youtube.com/MegynKellyTwitter: http://Twitter.com/MegynKellyShowInstagram: http://Instagram.com/MegynKellyShowFacebook: http://Facebook.com/MegynKellyShow Find out more information at: https://www.devilmaycaremedia.com/megynkellyshow
Marc and Kim dive into a packed hour on the Marc Cox Morning Show. First, they discuss St. Louis' new approach to snow removal, highlighting city updates. Then, Marc takes a hard look at the decline of the Boy Scouts of America, with a focus on their controversial decision to go genderless. He argues that this is the final blow to the organization, criticizing the broader cultural attack on masculinity. Marc laments the loss of spaces for young men to develop critical life skills. Kim then tackles a shocking incident from a youth hockey game in Seattle, where a father physically assaulted young referees. They discuss the alarming rise of aggressive behavior from parents at youth sports events, the emotional toll on referees, and the importance of holding adults accountable. Finally, the hosts touch on Dr. Naomi Wolf's explosive claims in The Pfizer Papers, questioning the safety and effectiveness of Pfizer's COVID-19 vaccine trials. #BoyScouts #AttackOnMasculinity #YouthSports #ParentingInSports #YouthReferees #SnowRemoval #StLouisNews #PfizerPapers #NaomiWolf #VaccinationControversy
Audio roundup of selected biopharma industry content from Scrip over the business week ended 7 February 2025. In this episode: Novo outlines CagriSema strategy; Pfizer is back in the deal game; Vertex's pain drug faces opportunities and headwinds; uncertain times for Korean pharma; and a view on women's health at JPM. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-Y37SM5W2TZDXNE26O3W6E33TZE/ Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things
The Super Bowl is the biggest advertising event of the year, with the biggest brands in the world flexing their advertising muscles (and budgets). A new entrant to the Super Bowl in 2024 was Pfizer, and they're back again this year with an ad that has blown the socks off the Pharma category. Their big game ad "Knock Out", scored 4.4 stars in System1 testing, also making it one of the best ads overall. I speak with Pfizer CMO, Susan Rienow about what it takes to create such a successful ad in the most competitive environment.Timestamps00:00 - Intro01:20 - Susan's successful career so far03:19 - What Pfizer does and their mission04:21 - The Covid vaccine rollout06:29 - The role of insights for making business decisions07:36 - Dealing with the complexities of different audiences10:12 - Managing the impact of fair balance in advertising14:51 - The role of Pfizer's advertising17:04 - Why have Pfizer gone all in with a Super Bowl ad20:12 - The Pfizer Super Bowl ad in 202525:20 - What role does testing play for creating an effective ad33:31 - The role of testing giving confidence to the board37:39 - How tiny changes can make such a big difference39:15 - How to evaluate the impact of a Super Bowl ad41:22 - What makes a great CMO46:40 - Advice Susan would give to young marketers
Early Triple Negative Breast Cancer remains an aggressive variant of all breast cancers, affecting those under 40 more and has a higher propensity for being in those with BRCA1/2 mutations. It represents about 15% of all breast cancers.This week, we explore the benefit of immunotherapy (pembrolizumab), looking at improved complete pathological response as a surrogate marker for OS and the role of capecitabine in the adjuvant setting.Studies discussed in the episode:CREATE-XKEYNOTE-522For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do. Hosted on Acast. See acast.com/privacy for more information.
Trump just floated the most jaw-dropping plan for Gaza we've ever heard—forget the UN and failed policies, he's talking about leveling it and rebuilding a booming resort economy that flips the entire Middle East script. Meanwhile, RFK Jr. just shook Big Pharma to its core, and the proof is in the numbers—Pfizer's stock TANKED the second he cleared his first confirmation hurdle!
Dawn Halkuff is a CEO, board member, and advisor. Having served under numerous influential companies, such as Pfizer and Guinness, Dawn has quite the resume. She is the CEO of LiviWell, a sexual health and wellness research and development company. Founded in 2019, LiviWell's goal is to transform sexual health and wellness with “clever design and clinical rigor.” Listen in as Dawn shares insights on entrepreneurship, corporate leadership, professional growth, and how she advocates for women in business. Links Dawn's LinkedIn: https://www.linkedin.com/in/dawnhalkuff/ LiviWell: https://liviwell.net/
Nine years with no evidence of disease—yet Megan-Claire Chase's cancer journey isn't over. As she once fought cancer alongside her mother, she now faces something even harder: losing her. In this episode, Megan-Claire shares a deeply vulnerable side—a daughter losing her mother. Facing your own mortality is one thing, but facing the mortality of your loved ones—friends, family, fellow cancer patients, and survivors—and the hole they leave behind is something entirely different. Key Highlights: Witnessing her mother's cancer progression brings anticipatory grief, yet despite that grief, Megan strives to learn as much about her mother as possible, including fond memories from her childhood. Despite the anticipatory grief, Megan and her mother engage in a bonding exercise using question cards, and she records their conversations. One of the most meaningful things she learned was that her mother reflects on her life with joy—ultimately, the greatest goal is to leave this world happy. Facing your own mortality can unearth many emotions: the need to be confident and not tolerate disrespect, the desire to live life on your own terms and to the fullest, yet also a deep sense of loneliness and isolation. About our guest: Check out the first episode Megan-Claire Chase appeared in here. Megan-Claire Chase, also known as Warrior Megsie, is the Breast Cancer Program Director and host of the Our BC Life podcast at SHARE Cancer Support. As an invasive lobular carcinoma (ILC) breast cancer survivor and passionate patient advocate based in Atlanta, GA, Megan-Claire is a dedicated champion for the needs of breast cancer patients, particularly in addressing the disparities faced by minoritized communities and those in the adolescent and young adult (AYA) communities. In addition to her pivotal role at SHARE, she serves on Bayer Oncology's Digital Patient Council, is a patient advocate for the Oncology Data Advisor Editorial Board, and recently joined the Worth the Wait Charity advisory board. She also contributes as a writer and advisory board member for Patient Power, amplifying the voices of breast cancer patients. Megan-Claire's advocacy efforts include participating as a panelist on Leveraging Technology to Support Patient-Centered Multidisciplinary Oncologic Care at the 2024 ASCO Quality Care Symposium, co-authoring a podcast and infographic on genetic testing in metastatic breast cancer, collaborating with Pfizer on the Action Guide to Disrupt Inequitable Health Outcomes, and sharing her personal journey on PBS's Beyond Cancer through Stories from the Stage. Her work has been spotlighted in notable publications like The New York Times, People Magazine, Cancer Health, Cancer Today, and CURE Magazine. Beyond her cancer advocacy, Megan-Claire is a versatile voiceover actor, a dedicated social justice activist, and a proud cat mom to Phoebe. Disclaimer: All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Looking for tools to help you take control of your cancer experience? Check out My Cancer GPS™, a step-by-step map that guides you through the entire cancer experience.
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Eli Lilly CEO David Ricks faced questions about potential oversupply of the company's drug Zepbound. Analysts are concerned that Lilly may have gone too far in expanding the supply chain for its GLP-1 drug. Meanwhile, Bristol Myers Squibb announced plans to increase cost-cutting measures and pursue new deals following the success of its drug Cobenfy. AstraZeneca discontinued two assets acquired from Alexion, despite exceeding Q4 earnings expectations. BMS reported $10 million in sales for Cobenfy in the fourth quarter of 2024.On the other hand, the AAPS National Biotechnology Conference will take place in May, covering trends in research and biopharma markets. X4 Pharmaceuticals and Viracta faced financial struggles, while Kura Oncology eyes FDA filing after a win in AML. Frontier Medicines announced staff cuts, but there is optimism for the job market in January. Pfizer is in discussions for new deals, including potential collaborations in China.Overall, job opportunities are available at companies like Amgen, Takeda, and Novo Nordisk.
We continue our NextGen Journeys series today featuring fresh perspectives on education, medicine, and the future of health care with an impressive medical student who was brought to our attention by a previous podcast guest, Dr. Michael Foti, whom we'd like to thank for the recommendation. Nikolas Bletnitsky is in his third year at Touro College of Osteopathic Medicine, Middletown, but that's just one element in his medical education. Over the last several years, Nick has done extensive work in the field of OB-GYN -- completing clinical electives in Paris, France and Bologna, Italy, in addition to the Mayo Clinic -- where he has pursued his intense interest in a variety of subspecialties, including maternal fetal medicine. “Right now I'm doing a lot because I'm young and I have the energy and I want to see a lot to give me different perspectives on things so that I can incorporate them into my own practice,” he tells host Michael Carrese. Join us for a wide-ranging conversation in which you'll learn about current practice in OB-GYN in the US and Europe, neonatal palliative care and advances in fetal surgery, along with what Nick has learned about having crucial conversations with the parents of patients when tough news needs to be discussed.Mentioned in this episode: Touro College of Osteopathic Medicine, If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast
The Rebel News podcasts features free audio-only versions of select RebelNews+ content and other Rebel News long-form videos, livestreams, and interviews. Monday to Friday enjoy the audio version of Ezra Levant's daily TV-style show, The Ezra Levant Show, where Ezra gives you his contrarian and conservative take on free speech, politics, and foreign policy through in-depth commentary and interviews. Wednesday evenings you can listen to the audio version of The Gunn Show with Sheila Gunn Reid the Chief Reporter of Rebel News. Sheila brings a western sensibility to Canadian news. With one foot in the oil patch and one foot in agriculture, Sheila challenges mainstream media narratives and stands up for Albertans. If you want to watch the video versions of these podcasts, make sure to begin your free RebelNewsPlus trial by subscribing at http://www.RebelNewsPlus.com
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Pfizer announces new breakthrough in cancer treatmentPfizer, a leading pharmaceutical company, has recently announced a major breakthrough in cancer treatment. Their new drug has shown promising results in clinical trials, with a significant increase in survival rates for patients with advanced stages of the disease. This development brings hope to millions of people affected by cancer worldwide.## FDA approves new diabetes medicationThe FDA has approved a new medication for the treatment of diabetes. This drug is expected to provide better blood sugar control and improve overall quality of life for patients with the condition. The approval is a significant milestone in the fight against diabetes, which affects millions of people globally.## Biogen partners with research institute to develop Alzheimer's treatmentBiogen, a biotechnology company, has partnered with a leading research institute to develop a new treatment for Alzheimer's disease. This collaboration brings together the expertise of both organizations to tackle one of the most challenging health issues facing society today. The potential impact of this partnership on Alzheimer's research is immense.## Novartis launches new vaccine for infectious diseaseNovartis, a pharmaceutical giant, has launched a new vaccine for an infectious disease that poses a threat to public health. This vaccine is expected to provide protection against the disease and help prevent its spread. The launch of this vaccine is a significant step forward in the fight against infectious diseases worldwide.## Roche acquires biotech startup for groundbreaking gene therapyRoche, a multinational healthcare company, has acquired a biotech startup that specializes in gene therapy. This acquisition will allow Roche to further develop groundbreaking treatments for genetic disorders and other diseases. The synergy between the two companies is expected to lead to innovative therapies that could revolutionize healthcare.## ConclusionIn conclusion, these recent developments in the pharmaceutical and biotech industry are groundbreaking and have the potential to transform healthcare as we know it. From breakthroughs in cancer treatment to advancements in diabetes medication, the future looks promising for patients around the world. Collaborations between industry leaders and research institutes are paving the way for innovative therapies that could have a lasting impact on global health. Stay tuned for more updates on the latest news and advancements in Pharma and Biotech.
U.S. political maneuverings are keeping biopharma on its toes. Tuesday, Robert F. Kennedy, Jr. passed a major hurdle as the Senate Finance Committee voted to advance his nomination for HHS secretary to a floor vote of the entire Senate. If confirmed, RFK Jr. could have an impact on myriad regulatory issues, including PDUFA negotiations. In other political news, Donald Trump announced his promised tariffs on Canada, Mexico and China—the last of which could have particular implications for biopharma companies looking to China for promising new drug candidates. Both were subjects of conversation as leading pharma companies—including Pfizer, Merck and Regeneron—reported their Q4 and full-year 2024 earnings. Notably, Pfizer is eyeing deals between $10 billion and $15 billion, while Merck took a 12% stock hit on Gardasil challenges in China and Regeneron issued its first-ever dividends. On the regulatory front, the FDA greenlit Vertex's Jounavx last week as the first new drug for acute pain in more than two decades. Journavx leads a non-opioid pain space that is seeing significant momentum this year, with Tris Pharma, Algiax Pharamceuticals and SiteOne Therapeutics all announcing positive data in the past month. Meanwhile, in obesity news, the U.K.'s pharmacies regulator rolled out stricter guidelines for online pharmacies selling medicines including Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, and an obesity-focused deal inked with Novo last year wasn't enough to keep Omega Therapeutics afloat as the Massachusetts-based biotech revealed it is heading toward bankruptcy. Finally, a new CEO will be taking the reins at Takeda in 2026—but the selection of Julie Kim is an exception in an industry still struggling for gender parity at the top leadership ranks.
A mixed morning for stocks as China announces retaliatory tariffs on some American imports like oil – Carl Quintanilla, Sara Eisen, and David Faber broke down the latest, beginning the hour with a fresh read from the ground in Beijing and some economic data (Factory Orders & JOLTS). Charles Schwab's Chief Investment Strategist gave her reaction to all the news - warning, “Tariffs delayed doesn't necessarily mean tariffs canceled”. Why she's forecasting potential pain – and higher inflation – ahead. Plus, a look at how retailers are preparing – and what it means for prices. Also a busy morning for earnings: Palantir shares surging on AI demand - why Jefferies is sticking by its sell call; More on Diageo results as the stock hits 2020 lows; What PepsiCo CEO thinks of tariffs – and quarterly results; And the biopharma breakdown after new numbers out of Merck and Pfizer
APAC stocks traded higher as the region reacted to US President Trump's delay of tariffs against Canada and Mexico for a month.However, the new 10% tariff on all China exports to the US took effect after the deadline passed.Furthermore, China is to levy countermeasures on some US imported products with 15% tariffs on coal and LNG, as well as 10% tariff on oil, agricultural machines and some autos from the US.European equity futures indicate a slightly lower cash market open with Euro Stoxx 50 future down 0.1% after the cash market closed with losses of 1.3% on Monday.DXY was boosted by Chinese retaliatory measures, EUR/USD is back below 1.03 and Cable is sub-1.24.Looking ahead, highlights include US JOLTS Job Openings, NZ HLFS Jobs, Riksbank Minutes, Fed's Bostic & Daly, Supply from UKEarnings from UBS, BNP Paribas, Vodafone, Diageo, Infineon, BMPS, Intesa Sanpaolo, Ferrari, AMD, Google, Snapchat, Chipotle, Amgen, Paypal, Spotify, Pfizer, Regeneron, PepsiCo, Merck, Estee Lauder, Marathon Petroleum.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk
New 10% tariffs on China exports to the US have taken effect; China is to levy countermeasures on some US imported products with 15% tariffs on coal and LNG, as well as 10% tariff on oil, agricultural machines and some autos from the US.European bourses trade tentatively, Tech buoyed by strength in Infineon; US futures are modestly lower.DXY is flat, JPY underperforms, unwinding the prior day's strength, and Antipodeans lag.Bonds pullback but remain above Monday's lows as we await tariff updates from US/China.Crude softer amid Canada/Mexico tariff delays and China tariff retaliation.Looking ahead, US JOLTS Job Openings, NZ HLFS Jobs. Speakers including Fed's Bostic & Daly.Earnings from BMPS, Intesa Sanpaolo, Ferrari, AMD, Google, Snapchat, Chipotle, Amgen, Paypal, Spotify, Pfizer, Regeneron, PepsiCo, Merck, Estee Lauder, Marathon Petroleum & Ball.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Trump's tariffs are expected to affect the pharmaceutical industry by leading to higher costs and lower margins for companies like J&J, AstraZeneca, Novo Nordisk, and Roche. This could result in financial setbacks for these companies. Meanwhile, GH's inhaled psychedelic has shown success in treating depression, which could provide a new treatment option for patients. In other news, Pfizer's Braftovi has shown promising results in a phase III trial for colorectal cancer, AbbVie's marketing misstep has impacted its aesthetics sales, and Takeda has dropped an epilepsy drug while appointing a new CEO. Overall, the pharmaceutical industry is experiencing various developments and challenges that could impact its future.
Hablamos de la macro del día en EE.UU y los resultados de Palantir, Pfizer, Pepsico, Alphabet y AMD. Con Ricardo Tomás, asesor del fondo Multigestión Basalto USA de Inversis Gestión SGIIC.